Home/Pipeline/Cabotegravir (LA) for PrEP

Cabotegravir (LA) for PrEP

HIV Prevention

Approved/Phase 3Active

Key Facts

Indication
HIV Prevention
Phase
Approved/Phase 3
Status
Active
Company

About ViiV Healthcare

ViiV Healthcare is a unique, HIV-focused pharmaceutical company established as a joint venture by GSK, Pfizer, and Shionogi. It has built a leading portfolio of antiretroviral therapies, including long-acting injectable regimens, and maintains a robust pipeline aimed at treatment, prevention, and cure. The company operates with a deep commitment to the HIV community, leveraging partnerships and implementation science to address unmet needs and health disparities globally.

View full company profile

Therapeutic Areas

Other HIV Prevention Drugs

DrugCompanyPhase
srRNA Vaccine for HIVReplicate BiosciencePre-clinical
GRAdHIVNE1ReiTheraPhase 1